Recent Comments

    Ebselen tagged posts

    Ebselen, abandoned as Stroke Rx, has Successful 1st human Trial as Repurposed Bipolar disorder Rx

    December 8, 2015, Categories  Biology/Biotechnology, Health/Medical

    double-blind, placebo-controlled trial with healthy participants, acute oral ebselen reduced brain myo-inositol in the anterior cingulate cortex, consistent with CNS target engagement. Ebselen decreased slow-wave sleep and affected emotional processing by increasing recognition of some emotions, decreasing latency time in the acoustic startle paradigm and decreasing the reinforcement of rewarding stimuli. In summary, ebselen affects the phosphoinositide cycle and has CNS effects on surrogate markers that may be relevant to the treatment of bipolar disorder, which can be tested in future clinical trials.

    Ebselen affects the phosphoinositide cycle and has CNS effects on surrogate markers that may be relevant to the treatment of bipolar disorder, which can be tested in future clinical trials.

    A drug destined for the scrap heap has been rescued by Oxford scientists. They used a database of ‘failed’ drugs, found to be safe but ineffective for their proposed use, to identify ebselen as a possible alternative to lithium, the main treatment for people who are bipolar.

    Ebselen was under development as a treatment for stroke, but was abandoned by its manufacturer in the final phase of clinical trials. However, those trials proved that the drug was safe for use in humans. Initial tests of ebselen as a treatment for bipolar disorder were carried out in mice...

    Read More